Year: 2019
Type: article
Abstract: OBJECTIVE: The objective was to describe a novel composite continuous glucose monitoring index (COGI) and to evaluate its utility, in adults with type 1 diabetes, during hybrid closed-loop (HCL) therapy and multiple daily injections (MDI) therapy combined with real-time continuous glucose monitoring (CGM). METHODS: COGI consists of three key components of glucose control as assessed by CGM: Time in range (TIR), time below range (TBR), and glucose variability (GV) (weighted by 50%, 35% and 15%). COGI ranges from 0 to 100, where 1% increase of time <3.9 mmol/L (<70 mg/dl) is equivalent to 4.7% reduction of TIR between 3.9-10 mmol/L (70-180 mg/dl), and 0.5 mmol/L (9 mg/dl) increase in standard deviation is equivalent to 3% reduction in TIR. RESULTS: < .001. CONCLUSIONS: COGI summarizes three key aspects of CGM data into a concise metric that could be utilized to evaluate the quality of glucose control and to demonstrate the incremental benefit of a wide range of treatment modalities.
Institutions: Manchester Academic Health Science Centre, University of Manchester, Manchester University NHS Foundation Trust, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Wellcome/MRC Institute of Metabolic Science, University of Bern, University Hospital of Bern, Medical University of Graz, Profil Institute for Metabolic Research, Dexcom (United States), Forschungsinstitut der Diabetes Akademie Mergentheim, University of Bamberg, Addenbrooke's Hospital
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Award: G8585681489
OpenAlex ID: W2917818735